NL-OMON36983已完成3 期
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer - Open label D'mab study in Subjects with Non-metastatic Prostate Cancer
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Subjects must be currently participating in the 20040138 study
排除标准
- •Subjects with any prior diagnosis of bone metastasis
- •Known hypocalcemia
- •Developed sensitivity to mammalian cell derived drug products during the 20040138 study.
- •Currently receiving any investigational product other than denosumab or having received any investigational product during the 20040138 study.
研究者
相似试验
撤回
3 期
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis10005959Postmenopausal osteoporosisNL-OMON30869Amgen62
进行中（未招募）
不适用
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab Administration in Postmenopausal Women with Low Bone DensityTreatment of postmenopausal osteoporosisMedDRA version: 17.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2007-001041-17-EEAmgen Inc.5,600
进行中（未招募）
不适用
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety ofDenosumab (AMG162) in the Treatment of Bone Loss in Subjects UndergoingAndrogen-Deprivation Therapy for Non-metastatic Prostate CancerEUCTR2008-006154-17-HUAmgen Inc803
进行中（未招募）
不适用
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab Administration in Postmenopausal Women with Low Bone DensityEUCTR2007-001041-17-DKAmgen Inc.5,600
进行中（未招募）
不适用
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab Administration in Postmenopausal Women with Low Bone DensityEUCTR2007-001041-17-LVAmgen Inc.5,600